| Detected | Trial | Change |
|---|---|---|
| 2026-08-06 | NCT06116110 Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
Primary endpoint(s) modified |
| 2026-08-06 | NCT06116110 Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
Trial sites expanded: 5 -> 11 locations |
| 2026-08-06 | NCT06116110 Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
date change Primary completion pushed: 2039-12-01 -> 2041-12-01 |
| 2026-08-06 | NCT06116110 Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
date change Completion pushed: 2039-12-01 -> 2041-12-01 |
| 2026-07-29 | NCT07717164 PRAISE-IR Versus CIBMTR Controls |
Primary endpoint(s) modified |
| 2026-07-25 | NCT03853616 MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) |
date change Primary completion pushed: 2026-06 -> 2026-09 |
| 2026-07-25 | NCT03853616 MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) |
date change Completion pushed: 2026-06 -> 2026-09 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-21 | NCT07717164 PRAISE-IR Versus CIBMTR Controls | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting |
| NCT06508931 | Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric… | B-Cell Neoplasm | Recruiting |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | Diffuse Large B-cell Lymphoma | Recruiting |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in… | Mantle Cell Lymphoma (MCL) | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06347718 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Systemic Lupus Erythematosus | Recruiting |
| NCT06189157 | MB-CART19.1 in Refractory SLE | SLE - Systemic Lupus Erythematosus | Recruiting |
| NCT06424340 | MB-dNPM1-TCR.1 in Relapsed/Refractory AML | Leukemia, Myeloid, Acute | Recruiting |
| NCT07178431 | MB-CART2019.1 in Refractory Multiple Sclerosis | Multiple Sclerosis | Recruiting |
| Phase 1 | |||
| NCT06708845 | US Zamto-cel Autoimmune Diseases | Lupus Nephritis | Recruiting |
| NCT03853616 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Acute Lymphoblastic Leukemia Recurrent | Active, Not Recruiting |
| Not specified | |||
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies | Melanoma Stage III | Recruiting |
| NCT06116110 | Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | Non Hodgkin Lymphoma | Recruiting |
| NCT06225050 | M-2018-334 in Hematological Malignancies | Hematological Malignancies | Not Yet Recruiting |
| NCT07717164 | PRAISE-IR Versus CIBMTR Controls | ALL (Acute B-Lymphoblastic Leukemia) | Not Yet Recruiting |